Analysis on Impact of COVID19-Global Mycoplasma Testing Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and ATCC

The global holographic display market size and it is poised to grow by USD 3504.54 million during 2020-2024, progressing at a CAGR of over 19% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Eon Reality Inc., Geola Digital uab, HoloTech Switzerland AG, Holoxica Ltd., Leia Inc., Lyncee Tec SA, Ovizio Imaging Systems NV/SA, RealView Imaging Ltd., vision optics GmbH, and zSpace Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The increased need for security has been instrumental in driving the growth of the market.

Holographic Display Market 2020-2024: Segmentation

Holographic Display Market is segmented as below:

·         Technology

o    Touchable

o    Semi-transparent

o    Laser

·         Geographic Landscape

o    North America

o    APAC

o    Europe

o    MEA

o    South America

 

Holographic Display Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our holographic display market report covers the following areas:

·         Holographic Display Market size

·         Holographic Display Market trends

·         Holographic Display Market industry analysis

This study identifies increasing applications of holographic displays in the healthcare sector as one of the prime reasons driving the holographic display market growth during the next few years.

Holographic Display Market 2020-2024: Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the holographic display market, including some of the vendors such as Eon Reality Inc., Geola Digital uab, HoloTech Switzerland AG, Holoxica Ltd., Leia Inc., Lyncee Tec SA, Ovizio Imaging Systems NV/SA, RealView Imaging Ltd., vision optics GmbH, and zSpace Inc. Backed with competitive intelligence and benchmarking, our research reports on the Holographic Display Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

 

Analysis on Impact of COVID19-Global Mycoplasma Testing Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and ATCC

The global mycoplasma testing market size is expected to grow by USD 445.57 million as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Moreover, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of over 11%.

Request for Technavio's latest reports on directly and indirectly impacted markets
Market estimates include pre- and post-COVID-19 impact on the mycoplasma testing market -

Download free sample report

The global outbreak of COVID-19 has compelled several companies in the healthcare industry to focus on finding a cure for this life-threatening disease. The number of pharmaceutical and biotechnology companies that focus on biomedical research is increasing, resulting in rising demand for mycoplasma testing to identify and eliminate mycoplasma contamination during the development of cell-derived biological and pharmaceutical products. However, the global outbreak of coronavirus is expected to have a neutral impact on the growth of the mycoplasma testing market during the forecast period.

The market is driven by the increasing focus on R&D of biopharmaceuticals. In addition, the growing M&A and partnerships between CROs, and pharmaceutical and biotechnology companies is anticipated to boost the growth of the mycoplasma testing market.

New class therapeutics such as cell therapy and gene therapy are gaining popularity as a novel treatment for many chronic and acute diseases. Thus, many pharmaceutical companies and research institutes are concentrating on the R&D of these products owing to their huge market potential. However, cell therapy products witness challenges around sterilization and its storage, as a result of which, it has to be immediately administered to the patients. Common mycoplasma species such as Acholeplasma laidlawii, Mycoplasma arginini, Mycoplasma bovis, Mycoplasma fermentans, and Mycoplasma salivarium have been identified as contamination in cell cultures and the biopharmaceutical processes. A product developed with mycoplasma contamination triggers serious side effects in humans. This is driving the demand for mycoplasma test kits. Rapid mycoplasma test kits are commercially available in the market that can be used in research labs and biopharmaceutical manufacturing companies for cell line qualification and in-process monitoring.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Mycoplasma Testing Companies:

Agilent Technologies Inc.

Agilent Technologies Inc. has business operations under various segments, such as life sciences and applied markets, diagnostics and genomics, and Agilent CrossLab. The company's key offerings include MycoSensor PCR Assay Kit, 50 Rxn, which is a gel-based PCR assay that can rapidly detect mycoplasma infections in the human cell lines in less than four hours.

ATCC

ATCC operates its business through various segments, such as classic media, specialty media, stem cell research, human cytogenetics, mycoplasma detection, and molecular biology. The company's key products include Universal Mycoplasma Detection Kit, which offers a quick and sensitive PCR-based test to detect mycoplasma contaminants in cell culture.

Becton, Dickinson and Co.

Becton, Dickinson and Co. has business operations under various segments, such as BD Medical, BD Life Sciences, and BD Interventional. The company's key offerings include BD MAX System, which is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. operates its business through two segments: pharmaceuticals and diagnostics. The company's key offerings include MycoTOOL PCR Mycoplasma Detection Kit, which tests the absence of mycoplasma in cell culture samples. It supplies all reagents for the amplification step. It is an in-vitro amplification test optimized for detection of mycoplasma in cell culture.

InvivoGen

InvivoGen has business operations under various segments, such as research fields, biological tools, and custom services. The company offers PlasmoTest, which is the first assay to utilize cells to signal the presence of mycoplasma. It is a simple, rapid, and reliable assay for the visual detection of mycoplasma contamination in cell cultures.